Enjoy complimentary customisation on priority with our Enterprise License!
The Chimeric Antigen Receptor (CAR) T-Cell Therapy Market size is estimated to grow at a CAGR of 13.44% between 2022 and 2027. The market size is forecast to increase by USD 1,999 million. The growth of the market depends on several factors, including the growing awareness regarding CAR T-cell therapy, the increasing prevalence of blood cancer, and the increasing incidence of hematological malignancies.
This car t-cell therapy market report extensively covers market segmentation by end-user (hospitals and cancer treatment centers), type (CD19, CD22, BCMA, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
The growing awareness regarding CAR T-cell therapy is notably driving the market growth, although factors such as the high cost associated with CAR T-cell therapy impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Growing awareness regarding CAR T-cell therapy is the key factor driving the growth of the market. As technology develops and CAR-T cells become more widely known, "armored CARs" are created that interact with cytokines like Interleukin 15 (IL-15) and Interleukin 12 (IL-12) that cause inflammation. It leads to the growth and persistence of CAR T cells at the beginning of immune suppression caused by cancer. Several governments have launched a number of initiatives to increase public awareness of these treatments to fund research into CAR T-cell therapies.
For instance, CAR T-cell therapy research and development, as well as numerous research facilities, were funded by the National Cancer Institute (NCI). Additionally, some governments have strengthened their backing for CAR T-cell treatments by introducing numerous initiatives such as new legislation, establishing benevolent reimbursement policies, working with private businesses, and conducting clinical research studies to raise public awareness of CAR T-cell treatments. These initiatives helped more people to become aware of CAR T-cell therapy which will increase the market growth during the forecast period.
One of the growing trends in the market is the rising number of product approvals and clinical trials related to CAR T- cell therapy. In recent years there has been a visible growth in product approval related to CAR T- cell therapy. For Instance, Yescarta was granted FDA approval in February 2022 as the first chimeric antigen receptor (CAR) T-cell therapy for the initial treatment of relapsed or refractory large B-cell lymphoma (LBCL). The first CAR T-cell therapy to receive a Category 1 recommendation in the NCCN Treatment Guideline is Yescarta. Similarly, in February 2022, the FDA approved ciltacabtagene autoleucel (Carvykti) for patients with multiple refractory myeloma-that is, multiple myeloma that has failed to respond to treatment.
According to the clinicaltrials.gov reports of November 23, 2022, there were about 415 clinical trials for CAR-T cell therapies registered, all of which were in various stages of development and cover both ongoing and completed studies as well as those that are actively recruiting study participants. These factors are considered the driving force of the global CAR T- cell therapy market during the forecast period.
The high cost associated with CAR T-cell therapy is considered to be one of the significant challenges faced by the market. The cost of CAR T-cell therapies is influenced by numerous factors, such as the personalized nature of the therapy, the complex manufacturing process, and the specialized requirements of healthcare infrastructure. For instance, CAR T-cell therapies involve a multi-step process that starts with collecting a patient's own T-cells through leukapheresis. The T-cells are then modified in the laboratory to express a chimeric antigen receptor (CAR) specific to the target antigen, expanded in quantity, and reinfused back into the patient.
However, this manufacturing process requires specialized facilities, equipment, and expertise, which contribute to the overall cost of the therapy. Moreover, CAR T-cell therapies are personalized treatments tailored to each patient. The manufacturing process for each patient is individualized, adding to the complexity and cost. Furthermore, the extensive clinical trials and research involved in developing CAR T-cell therapies also contribute to the overall cost burden. CAR T-cell therapies are not widely available even though there are numerous outstanding results in clinical trials. Such factors will hinder the market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global CAR T-Cell Therapy Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
ACROBIOSYSTEMS INC: The company offers CAR T-cell therapy called CD37 plus CD22 CAR T, which is in the research phase PCC.
The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the hospitals segment will be significant during the forecast period. Hospitals provide post-treatment follow-up care to monitor the patient's long-term outcomes, manage any lingering side effects, and detect any signs of disease recurrence or relapse. Hence the growing treatments related to cancer in hospitals are expected to drive the growth of the hospital segment in the global CAR T-cell therapy market during the forecast period.
Get a glance at the market contribution of various segments View the PDF Sample
The hospitals segment was valued at USD 752.77 million in 2017 and continued to grow until 2021. Hospitals provide the necessary infrastructure, medical staff, and resources for the administration of CAR T-cell therapies. They have specialized oncology departments or treatment centers equipped to deliver these therapies to eligible patients. Healthcare professionals, including oncologists, hematologists, and nurses, are responsible for managing the treatment process related to CAR T-cell therapy, ensuring patient safety, and monitoring the response to therapy.
Moreover, hospitals play a vital role in identifying eligible patients for CAR T-cell therapy. They assess patient's medical history, perform diagnostic tests, and evaluate their suitability for treatment. This involves considering factors such as the type and stage of cancer, previous treatment history, and overall health condition. Additionally, they may conduct pre-treatment evaluations, including imaging studies and laboratory tests, to establish a baseline and monitor the patient's progress during and after therapy. Such factors will increase segment growth during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The major reason behind the rising prevalence of chronic illnesses like cancer and autoimmune diseases such as myasthenia gravis (MG), the expansion of research and development activities, and the presence of well-established and powerful market players such as Gilead Sciences, Inc. in the region. Moreover, the rise in investments helps in the expansion of the market.
For instance, in June 2021, Blackstone reported that Cellex Cell Professionals GmbH, the parent company of GEMoaB GmbH, a clinical-stage cell therapy company, and Intellia Therapeutics, Inc. had committed $ 250 million to the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company. As a result of an increase in cancer cases and the rise in clinical studies in CAR T-Cell therapies, the country is anticipated to experience growth over the forecast period.
The CAR T-cell therapy market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Technavio categorizes the global CAR T-cell therapy market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.
|
CAR T-Cell Therapy Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
153 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 13.44% |
|
Market growth 2023-2027 |
USD 1,999 million |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
13.12 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 41% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
ACROBIOSYSTEMS INC., Allogene Therapeutics Inc., Autolus Therapeutics plc, Bristol Myers Squibb Co., Celyad Oncology SA, Eli Lilly and Co., Fate Therapeutics Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier SAS, Merck KGaA, Miltenyi Biotec B.V. and Co. KG, Noile Immune Biotech Inc., Novartis AG, Pfizer Inc., Sangamo Therapeutics Inc., Sorrento Therapeutics Inc., TCR2 Therapeutics Inc., and Fortress Biotech Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
